Literature DB >> 11172296

Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer.

M S Tsao1, Y Yang, A Marcus, N Liu, L Mou.   

Abstract

Hepatocyte growth factor (HGF) exerts multifunctional regulatory roles in the growth, morphogenesis, differentiation, and motility of epithelial cells, and putatively plays important roles in tumor angiogenesis and metastasis. Aside from the full-length protein, 2 naturally occurring truncated HGF isoforms (NK1 and NK2) have been identified. Recent evidence suggests that a high level of HGF in surgically resected non-small-cell lung carcinoma (NSCLC) is a negative prognostic marker for NSCLC patients' survival. The origin of HGF in these tumors remains uncertain. We show here by in situ hybridization and immunohistochemistry that HGF messenger RNA (mRNA) and protein were predominantly expressed by the tumor cells in a high percentage of primary NSCLC. Stromal cell expression of HGF was limited to some lymphocytes and endothelial cells. Normal bronchial and bronchiolar epithelial cells also expressed HGF mRNA and immunoreactive protein. The mRNA transcripts and putative proteins of all 3 known HGF isoforms were detected in both normal lung and lung cancer tissues, but the full-length HGF was predominantly expressed. Our findings indicate that both autocrine and paracrine functions of HGF are likely to contribute to the pathobiology of lung cancer in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172296     DOI: 10.1053/hupa.2001.21133

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

Review 1.  MET targeted therapy for lung cancer: clinical development and future directions.

Authors:  Yan Feng; Patrick C Ma
Journal:  Lung Cancer (Auckl)       Date:  2012-08-09

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Significance of plasma hepatocyte growth factor in diagnosis of benign and malignant solitary pulmonary nodules.

Authors:  Haixin Yu; Yan Wang; Qian Yu; Haiyan Zhang; Wenduan Ma; Shengtao Shang; Donglin Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Combined treatment with MET inhibitors and other therapies in lung cancer.

Authors:  Rakesh Bagai; Patrick C Ma
Journal:  Transl Lung Cancer Res       Date:  2012-09

Review 5.  Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Authors:  Giovanna Finocchiaro; Luca Toschi; Letizia Gianoncelli; Marina Baretti; Armando Santoro
Journal:  Ann Transl Med       Date:  2015-04

6.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Authors:  George M Burslem; Blake E Smith; Ashton C Lai; Saul Jaime-Figueroa; Daniel C McQuaid; Daniel P Bondeson; Momar Toure; Hanqing Dong; Yimin Qian; Jing Wang; Andrew P Crew; John Hines; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

Review 7.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:  Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-10-26       Impact factor: 15.609

8.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

9.  Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Hyori Kim; Jeonghwan Youk; Yaewon Yang; Tae-Yong Kim; Ahrum Min; Hye-Seon Ham; Seongcheol Cho; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Do-Youn Oh; Han Suk Ryu; Wonshik Han; In Ae Park; Tae-You Kim; Dong-Young Noh; Seock-Ah Im
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

Review 10.  Molecular pathways and therapeutic targets in lung cancer.

Authors:  Emma Shtivelman; Thomas Hensing; George R Simon; Phillip A Dennis; Gregory A Otterson; Raphael Bueno; Ravi Salgia
Journal:  Oncotarget       Date:  2014-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.